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Considerable evidence implicates hypoxia and vascular inflammation in Alzheimer’s
disease (AD). Thrombin, a multifunctional inflammatory mediator, is demonstrable in the
brains of AD patients both in the vessel walls and senile plaques. Hypoxia-inducible
factor 1α (HIF-1α), a key regulator of the cellular response to hypoxia, is also upregulated
in the vasculature of human AD brains. The objective of this study is to investigate
inflammatory protein expression in the cerebrovasculature of transgenic AD mice and to
explore the role of thrombin as a mediator of cerebrovascular inflammation and oxidative
stress in AD and in hypoxia-induced changes in brain endothelial cells. Immunofluorescent
analysis of the cerebrovasculature in AD mice demonstrates significant (p < 0.01–0.001)
increases in thrombin, HIF-1α, interleukin-6 (IL-6), monocyte chemoattractant protein-1
(MCP-1), matrix metalloproteinases (MMPs), and reactive oxygen species (ROS) compared
to controls. Administration of the thrombin inhibitor dabigatran (100mg/kg) to AD mice
for 34 weeks significantly decreases expression of inflammatory proteins and ROS.
Exposure of cultured brain endothelial cells to hypoxia for 6 h causes an upregulation
of thrombin, HIF-1α, MCP-1, IL-6, and MMP2 and ROS. Treatment of endothelial cells
with the dabigatran (1 nM) reduces ROS generation and inflammatory protein expression
(p < 0.01–0.001). The data demonstrate that inhibition of thrombin in culture blocks the
increase in inflammatory protein expression and ROS generation evoked by hypoxia.
Also, administration of dabigatran to transgenic AD mice diminishes ROS levels in brain
and reduces cerebrovascular expression of inflammatory proteins. Taken together, these
results suggest that inhibiting thrombin generation could have therapeutic value in AD and
other disorders where hypoxia, inflammation, and oxidative stress are involved.
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INTRODUCTION
Alzheimer’s disease (AD) is a complex, multifactorial neurode-
generative disease that affects more than 5.3 million people in the
United States (Ballard et al., 2011; www.alz.org). The processes
and factors that drive disease pathogenesis are not well delin-
eated, although considerable literature suggests that vascular risk
factors and vascular pathology are important (Farkas and Luiten,
2001; de la Torre, 2002; Knopman and Roberts, 2010; Grammas,
2011). Neurovascular abnormalities have been extensively docu-
mented in AD (Bell and Zlokovic, 2009) and abnormal vascular
function could impact neuronal viability in multiple ways (de la
Torre, 2000; Grammas, 2011; Sengillo et al., 2012). Inflammation
and hypoxia are important mechanisms implicated in the devel-
opment of AD (Kalaria, 2000; Grammas and Ovase, 2001, 2002;
Peers et al., 2007; Grammas et al., 2011; Broussard et al., 2012;
Carnevale et al., 2012).
In the brains of AD patients, as well as in animal models of
AD, numerous reports document upregulation of a wide variety
of inflammatory proteins (Rubio-Perez and Morillas-Ruiz, 2012;
Zhang et al., 2013). Expression of proinflammatory cytokines and
other inflammatorymediators are clearly demonstrable in regions
of the brainmost associated with AD pathology (Xia and Hyman,
1999). Also, a role for inflammation as a driver of pathologic
events in the AD brain is supported by studies that show phar-
macologic inhibition of inflammation through prolonged use of
non-steroidal anti-inflammatory drugs significantly reduces the
risk of developing AD (In’t Veid et al., 2002; Etminan et al., 2003;
Hoozemans et al., 2003). The cerebrovasculature is likely an active
participant in neuroinflammation as a large number of inflamma-
tory proteins including thrombin, tumor necrosis factor (TNFα),
interleukin (IL)-1, IL-6, IL-8, monocyte chemoattractant pro-
tein (MCP)-1, and matrix metalloproteinases (MMPs) are over
expressed in AD-derived vessels compared to vessels from age-
matched controls (Grammas and Ovase, 2001; Grammas et al.,
2006, 2011; Thirumangalakudi et al., 2006).
Inflammation and hypoxia are interrelated processes; hypoxia
can elicit tissue inflammation and inflamed tissues frequently
become hypoxic (Himadri et al., 2010; Imtiyaz and Simon, 2010;
Eltzschig and Carmeliet, 2011; Koeppen et al., 2011). Cerebral
hypoperfusion, leading to hypoxia, has been implicated as an
important underlying factor that promotes dementia (Peers et al.,
2009; Daulatzai, 2012). Hypoxia triggers a cascade of events that
contribute to the pathologic processes of AD through activation
of multiple pathways (Sharp and Bernaudin, 2004; Zhang and Le,
2010). In this regard, hypoxia has profound effects on vascula-
ture and has been shown to modulate endothelial reactive oxygen
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species (ROS) generation and to stimulate a pro-inflammatory
gene expression (Giordano, 2005; Sanchez et al., 2012). The
transcriptional factor hypoxia inducible factor (HIF)-1α, a pri-
mary sensor of low oxygen tension and a regulatory molecule
which controls the cellular response to hypoxia, is elevated in
the cerebromicrocirculation of AD patients and AD transgenic
mice (Grammas et al., 2006, 2011). Finally, a link between cere-
brovascular inflammation and hypoxia is further suggested by
data showing that the inflammatory proteins elevated in the
brain microvasculature of AD patients and/or AD mice are also
increased in brain endothelial cells exposed to hypoxia (Grammas
et al., 2011; Sanchez et al., 2013).
Many of the inflammatory proteins over expressed in the
AD cerebrovasculature have detrimental effects on neurons.
Thrombin, amultifunctional inflammatory mediator demonstra-
ble in the brains of AD patients both in the vessel walls and senile
plaques (Akiyama et al., 1992; Yin et al., 2010), is likely a cen-
tral mediator of neuronal injury. Thrombin is directly toxic to
neurons and can also potentiate neuronal injury indirectly via
activation of neighboring microglia and astrocytes (Choi et al.,
2003, 2005, 2008). In this regard, thrombin’s neurotoxic proper-
ties have been extensively documented both in vitro and in vivo
(Turgeon et al., 1999; Reimann-Philipp et al., 2001; Mhatre et al.,
2004). Administration of thrombin directly into the rat brain
results in neuronal cell death, glial scarring, and cognitive deficits
(Mhatre et al., 2004). Also, exposure of microglia or astrocytes
to thrombin results in increased release of noxious ROS and
MMPs (Choi et al., 2005, 2008). Because thrombin, a key med-
itator of angiogenesis, is elevated in response to hypoxia (Landau
et al., 2000), this protein could be an important regulator of the
cerebrovascular response to hypoxia in AD.
The objective of this study is to investigate thrombin, HIF-1α,
and inflammatory protein expression in the cerebrovasculature
of transgenic AD mice and to explore the role of thrombin as a
mediator of cerebrovascular inflammation in AD and hypoxia-
mediated inflammation.
MATERIALS AND METHODS
CULTURE AND HYPOXIC EXPOSURE OF RAT BRAIN ENDOTHELIAL
CELLS
Brain endothelial cell cultures were obtained from rat brain
microvessels, as previously described (Diglio et al., 1993). The
purity of these cultures was confirmed using antibodies to the
endothelial cell surface antigen Factor VIII. Endothelial cells used
in this study (passages 8–15) were maintained in Dulbecco’s mod-
ified Eagle’s medium (DMEM, Sigma-Aldrich, St. Louis, MO)
supplemented with 10% fetal bovine serum (FBS), 1% antibi-
otic/antimycotic, and 2mMglutamine. Confluent endothelial cell
cultures were washed three times with Hank’s balanced salt solu-
tion (HBSS, Gibco, Grand Island, NY) and then incubated at
37◦C with serum-free DMEM for 6 h under hypoxic (1% O2) or
normoxic (21% O2) conditions.
MEASUREMENT OF CELL SURVIVAL BY MTT ASSAY
Cells were washed with phosphate buffer saline (PBS) and incu-
bated with the MTT reagent 3-(4,5-dimethylthiazol-2-yl)-2-5-
diphenyl tetrazolium bromide (1:40 dilution) for 5–10min at
37◦C. The cells convert the MTT reagent to formazan which
is quantified by colorimetric assay (Cell Titer 95 Aqueous
solution cell proliferation assay, Promega, Madison, WI). The
formazan product was read at 490 nm. The number of con-
trol cells, i.e., viable cells not exposed to any treatment, was
defined as 100%.
ADMINISTRATION OF THROMBIN INHIBITOR TO MICE AND
IMMUNOFLUORESCENT STAINING OF MICE BRAIN SECTIONS
Adult wild-type 3xTgAD—LaFerla (control) and 3xTgAD—
LaFerla mice were purchased at 8 weeks of age from The Jackson
Laboratory (Bar Harbor, ME). Daily administration of the orally
available direct thrombin inhibitor (DTI) dabigatran etexylate
(Pradaxa®, Boehringer Ingelheim, Germany) (100mg/kg) in PBS
to AD mice and vehicle to control mice began at 18 weeks of
age and continued daily for 34 weeks. DTI was administered
in food. To ensure all food, and therefore drug, was consumed
while maintaining ad libitum weight, mice were weighed and
food intake monitored daily. All animal procedures were per-
formed in accordance with NIH “Guide for the Care and Use of
Laboratory Animals” and Texas Tech University Health Sciences
Center Institutional Animal Care and Use Committee (IACUC)
guidelines.
Mice were euthanized and brain tissue fixed with 10% neu-
tral buffered formalin (NBF). The brain was removed and 1mm
blocks of tissue from cerebral cortex were post fixed in 10%
NBF for additional 12 h and embedded in paraffin. Brain sec-
tions from the frontal cortex (7μm thick) were deparaffinized
in xylene, hydrated through a graded alcohol series, and then
rinsed for 5min in deionized water. Sections were subjected
to heat-induced epitope antigen retrieval, washed with Tris-
buffered saline with Tween (TBST) and blocked with 10% donkey
serum at room temperature for 2 h. The sections were incu-
bated at 4◦C overnight with primary antibodies against HIF-1α
(ab1, Abcam, Cambridge, MA), thrombin (sc16972, Santa Cruz
Biotechnology, Santa Cruz, CA), MMP2 (ab37150, Abcam), IL-6
(ab6672, Abcam), MCP-1 (ab9858, Abcam), or the endothe-
lial cell marker von Willebrand Factor (vWF, sc114014, sc8068,
Santa Cruz) in TBS containing 2.5% donkey serum. Sections
were then washed, blocked, and incubated with appropriate sec-
ondary antibodies conjugated with Alexa Fluor 488 or Alexa Fluor
594. Sections (3 per mouse) were incubated with DAPI solution
at room temperature for 25min and viewed using an Olympus
IX71 microscope and quantified with HAMAMATSU imaging
software.
DETECTION OF REACTIVE OXYGEN SPECIES IN CELL CULTURE AND
MOUSE BRAIN TISSUE SECTIONS
Brain endothelial cell cultures were grown on coverslips in 24-well
plates, incubated at 37◦C in serum free media with or with-
out dabigatran (DTI, 1 nM) and exposed to hypoxic (6 h, 1%
O2) or normoxic (21% O2) conditions. Sections from frozen
brain (10–20μm thickness) were placed on coverslips in 24-well
plates with 0.5ml of PBS at room temperature. Brain sections
and cell cultures were incubated with 5μM of dihydroethidium
(DHE) fluorescence dye (Life Technologies, Grand Island, NY;
D23107) and Hoechst33342 NucBlue stain (Life Technologies,
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R37605) for 30min in the dark at room temperature. DHE is a
cell permeable compound which reacts with intracellular ROS to
form oxyethidium, which emits a bright red color detectable by
fluorescent microscopy. Following two washes with PBS, images
were captured immediately using an Olympus IX71 microscope
and analyzed using HAMAMATSU imaging software.
REAL-TIME PCR ANALYSIS
RNA from cultured rat brain endothelial cells was pre-
pared using the TRI Reagent RT (Molecular Research Center,
Inc., Cincinnati, OH), according to manufacturer protocol.
Four micrograms of total RNA were reverse transcribed
using oligo dT primers and Transcriptor high fidelity reverse
transcriptase according to the manufactures protocol (Roche
Applied Science). Real-time PCR was performed using the
Applied Biosystems 7900HT fast real time PCR system.
Taqman gene expression master mix and Taqman gene expres-
sion assays from Applied Biosystems (Weiterstadt, Germany)
were used for PCR. Primers for Thrombin (rat: Assay ID
Rn00575908_m1, mice: Mm00438843_m1), HIF-1α (rat: Assay
ID Rn00577560_m1, mice: Mm00468869_m1), MMP2 (rat:
Assay ID Rn01538170_m1, mice: Mm00439498_m1), IL-6 (rat:
Assay ID Rn01410330_m1, mice: Mm00446190_m1), MCP-1
(rat: Assay ID Rn00580555_m1, mice: Mm00441242_m1), and
actin (rat: Assay ID Rn00667869_m1, mice: Mm00607939_s1)
were used for these experiments. Results were normalized to
actin. Fold difference between two samples (relative quantifica-
tion) was determined by use of the delta–delta method [S1/S2 =
2 − (T1 − T2)], where S1 and S2 represent samples 1 and 2, and
T1 and T2 represent the threshold cycles of samples 1 and 2,
respectively.
STATISTICAL ANALYSIS
Data from each experiment are expressed as mean ± standard
deviation (SD). The One-Way ANOVA followed by Bonferroni’s
comparison tests were performed for multiple samples. Statistical
significance was determined at p < 0.05.
RESULTS
THROMBIN INHIBITION AFFECTS THE INFLAMMATORY RESPONSE OF
BRAIN ENDOTHELIAL CELLS EXPOSED TO HYPOXIA
Brain microvessel endothelial cell cultures were incubated with
the DTI dabigatran (10 pM–100nM), exposed to hypoxia for 6 h
and cell viability measured by MTT assay. There was a mod-
est (19%) but significant (p < 0.05) increase in cell survival at
1–10 nM DTI while DTI doses in excess of 100 nM were toxic.
Exposure of endothelial cultures to DTI under normoxic condi-
tions did not affect cell survival at doses under 100 nM (data not
shown).
In contrast to the modest effects on cell survival, thrombin
inhibition had profound effects on inflammatory gene expression
in endothelial cell cultures exposed to hypoxia. Real-time PCR
analysis of RNA collected from brain endothelial cells exposed to
6 h hypoxia showed a significant (p < 0.001) increase in mRNA
for HIF-1α as well as for several inflammatory-associated genes
including thrombin, IL-6, MCP-1, and MMP2. Treatment of
endothelial cells with the thrombin inhibitor (1 nM) significantly
(p < 0.01–0.001) reduced hypoxia-mediated effects on inflam-
matory gene expression (Figure 1).
TREATMENT OF AD MICE WITH DTI REDUCES CEREBROVASCULAR
EXPRESSION OF HIF-1α AND INFLAMMATORY PROTEINS
Microvessels from frontal cortex sections were examined by
immunofluorescence from control and AD transgenic mice as
well as control and AD mice that received 34 weeks of daily DTI
administration (100mg/kg). A comparison between control and
ADmice showed that there was a significant (p < 0.001) increase
in cerebrovascular expression in AD mice of HIF-1α, thrombin,
IL-6, MCP-1, and MMP2 (Figure 2). Treatment of AD mice with
DTI significantly (p < 0.05–0.001) reduced expression of these
proteins (Figure 2).
DABIGATRAN REDUCES EXPRESSION OF HIF-1α, THROMBIN, IL-6,
MCP-1, AND MMP2 IN THE BRAINS OF AD TRANSGENIC MICE
Examination of brain samples from AD transgenic mice by real
time PCR demonstrated that expression of RNA for HIF-1α,
thrombin, IL-6, MCP-1, andMMP2 was significantly (p < 0.001)
increased compared to levels in control animals. Similar to the
data obtained for cerebrovascular expression (Figure 2), exam-
ination of brain tissues also showed a significant (p < 0.01 to
p < 0.001) decrease in RNA levels of these same proteins in AD
mice that received DTI (Figure 3).
GENERATION OF ROS IN AD MICE AND HYPOXIC ENDOTHELIAL CELL
CULTURES IS INHIBITED BY DABIGATRAN
The effect of DTI on ROS level in brain tissue sections from
frontal cortices of AD transgenic mice was assessed using the flu-
orescence dye DHE. Quantitation of DHE levels showed that ROS
generation was 8-fold higher (p < 0.001) in sections from AD
mice brains compared to sections from control mice (Figure 4).
Administration of DTI for 34 weeks to AD mice significantly
(p < 0.001) decreased DHE level compared to untreated ADmice
(Figure 4).
An examination of cultured brain endothelial cells exposed to
6 h hypoxia showed a significant (p < 0.001) increase in ROS lev-
els, as assessed by an increase in DHE fluorescence. Treatment
of endothelial cell cultures with DTI blocked (p < 0.001) this
increase in hypoxia-induced ROS generation (Table 1).
DISCUSSION
The results of the current study define thrombin as a keymediator
in the cerebrovascular response to hypoxia. The data demon-
strate that inhibition of thrombin in culture blocks the increase
in inflammatory protein expression and ROS generation evoked
by hypoxia. Also, administration of the thrombin inhibitor DTI
to transgenic AD mice diminishes expression of inflammatory
proteins and ROS in the cerebromicrovasculature of those mice.
Taken together, these results suggest that inhibiting thrombin
generation could have therapeutic value in AD and other dis-
orders where hypoxia, inflammation, and oxidative stress are
involved.
The role of vascular risk factors in the development of AD
is increasingly recognized. Although risk factors such as hyper-
cholesterolemia, hyperhomocysteinemia, and diabetes may affect
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FIGURE 1 | Brain microvascular endothelial cell cultures were
treated with 1nM direct thrombin inhibitor, dabigatran (DTI) and
were exposed to hypoxia for 6h. Total RNA was collected, reverse
transcribed, and mRNA expression of HIF-1α, thrombin, IL-6, MCP-1,
and MMP2 determined by real-time PCR. Data are from four separate
experiments performed in triplicate and expressed as fold change over
control (C). ∗∗∗p < 0.001 vs. C (control); ap < 0.001, bp < 0.01 vs. H
(hypoxia).
the brain in multiple ways, the injurious effects of these risk fac-
tors on the cerebrovasculature likely contribute to deleterious
events in the AD brain (Knopman and Roberts, 2010; Grammas,
2011). Vascular inflammation is a common mechanistic path-
way activated by hypercholesterolemia, hyperhomocysteinemia,
diabetes as well as other vascular risk factors (Rojo et al., 2008;
Rosenbaum et al., 2012). Hypoxia, thought to trigger degener-
ative changes in the brain that contribute to the development
of dementia, also has profound effects on the inflammatory
response of the vasculature (Grammas et al., 2011; Daulatzai,
2012). The cerebrovasculature may be a locus where multiple
pathogenic processes converge and contribute to compromised
neurovascular function.
Hypoxia and the multifunctional protein thrombin are linked.
Hypoxia stimulates angiogenesis and thrombin is a key medi-
ator of the angiogenic process (Dupuy et al., 2003; Green and
Karpatkin, 2010; Zhou et al., 2012). Beyond its central role in
the coagulation cascade, thrombin can directly affect cellular pro-
cesses in a variety of cell types including endothelial cells, glia,
and neurons (Lee da et al., 2006; Huang et al., 2008; Zundorf and
Reiser, 2011; Alabanza and Bynoe, 2012). There is an extensive
literature identifying the ability of hypoxia-stimulated periph-
eral endothelial cells to express a proangiogenic/inflammatory
phenotype that is mediated by thrombin (Chen et al., 2010; Sabit
et al., 2010). However, the response of peripheral endothelial cells
to thrombin may not necessarily reflect the response of the highly
specialized endothelial cells that comprise the blood-brain bar-
rier. Using a human cell line, thrombin has been shown to induce
an inflammation in brain endothelia (Alabanza and Bynoe, 2012).
Also, in rodent-derived brain endothelial cells thrombin can elicit
a pro-inflammatory phenotype (Zhou et al., 2012). Studies have
shown that brain endothelial cells can both synthesize throm-
bin as well as respond to exogenously applied protein (Yin et al.,
2010). Thrombin could, therefore, function as an autocrine fac-
tor that can regulate endothelial cell activation in the brain.
The data herein which document the ability of DTI to abrogate
the pro-inflammatory effects of hypoxia support a central role
for thrombin as a regulator of the cerebrovascular response to
hypoxia and contribute to a growing literature that implicates
thrombin in neuroinflammatory conditions in the brain.
The ability of hypoxia to induce vascular inflammation has
important implications for the pathogenesis of neurodegenera-
tive diseases such as AD which are associated with hypoperfusion
and hypoxia. Neuroinflammation has been extensively demon-
strated in the AD brain (Niranjan, 2013). Cytokines and other
inflammatory proteins are elevated in human AD as well as in
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FIGURE 2 | Brain tissues from control, control + DTI, AD and
AD + DTI AD mice were fixed and immunostained with HIF-1α,
thrombin, IL-6, MCP-1, and MMP2 primary antibodies and
fluorescence labeled secondary antibody (green). The bar graph
denotes signal intensities normalized to endothelial specific marker von
Willebrand factor (vWF, red) and control values set to 1. Data are
from four mice per group. ∗p < 0.05, ∗∗∗p < 0.001 vs. C (control);
ap < 0.001, cp < 0.05 vs. AD.
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FIGURE 3 | Brain tissues from control, control + DTI, AD and AD + DTI
mice were homogenized, total RNA collected, reverse transcribed and
mRNA expression of HIF-1α, thrombin, IL-6, MCP-1, and MMP2
determined by real time PCR. Data are from four mice per group and
expressed as fold change over control (C, untreated). ∗∗∗p < 0.001 vs. C
(control); ap < 0.001, bp < 0.01 vs. AD.
transgenic animalmodels (Rubio-Perez andMorillas-Ruiz, 2012).
Retrospective epidemiological studies suggest that a wide vari-
ety of non-steroidal anti-inflammatory drugs significantly reduce
one’s lifetime risk of developing AD (In’t Veid et al., 2002;
Etminan et al., 2003; Hoozemans et al., 2003) further supporting
the importance of neuroinflammation in disease pathogenesis.
In AD there is a robust elevation in inflammatory media-
tors in the cerebral microcirculation. Compared to microves-
sels from age-matched controls, AD brain microvessels release
significantly higher levels of a number of inflammatory fac-
tors including nitric oxide (NO), thrombin, TNF-α, transform-
ing growth factor-β (TGF-β), IL, IL-1β, IL-6, IL-8, and MMPs
(Grammas et al., 2006, 2011; Thirumangalakudi et al., 2006).
Thus, previous work and the data presented in the current study
which documents that hypoxia evokes increased cerebrovascu-
lar expression of the same inflammatory proteins documented
both in human AD and transgenic AD mice strengthens the
argument suggesting a role for hypoxia-mediated effects in the
pathogenesis of AD.
Release of vascular-derived inflammatory proteins could stim-
ulate/activate neighboring glial cells, both microglia and astro-
cytes, to release inflammatory proteins as well as noxious ROS
and proteases. This noxious neurotoxic cycle could be augmented
by vascular-derived thrombin. In addition to thrombin’s inflam-
matory effects on brain endothelia, thrombin could contribute to
deleterious and self-perpetuating neuroinflammation via induc-
tion of proinflammatory cytokines including IL-1β, IL-6, TNFα
in microglia, and astrocytes (Choi et al., 2003, 2008; Lee da et al.,
2006; Huang et al., 2008). Our data showing administration of the
thrombin inhibitor DTI to AD mice reduces vascular expression
of inflammatory proteins further supports an important role for
thrombin as a mediator of neuroinflammation.
The results of the current study show that administration of
DTI to AD mice reduces ROS generation in the brain, as assessed
by an increase inDHEfluorescence. Also, treatment of endothelial
cell cultures with DTI blocks hypoxia-induced ROS generation.
The generation of ROS by brain endothelial cells in response to
hypoxia is, in addition to inflammation, a destructive mechanism
that likely contributes to pathologic changes in the AD brain.
In this regard, there is a large literature documenting increased
oxidative stress and ROS generation in the AD brain (Mecocci
et al., 1994; Good et al., 1996; Nunomura et al., 2006). Indeed,
elevated oxidative stress is an invariant finding in AD. Markers of
oxidative stress such as protein, lipid, and DNA oxidation appear
Frontiers in Aging Neuroscience www.frontiersin.org May 2013 | Volume 5 | Article 19 | 6
Tripathy et al. Thrombin in AD and hypoxia
FIGURE 4 | Brain tissue sections from frontal cortices from control,
control + DTI, AD, and AD + DTI mice were incubated for 30min with
5μM of Dihydroethidium (DHE, red) fluorescence dye, and NucBlue
stain (blue). Data represents signal intensities of DHE stained cells to
non-stained cells. ∗∗∗p < 0.001 vs. control (C); ap < 0.001 vs. AD.
Table 1 | ROS levels in cultured brain endothelial cells.
Control Control + DTI Hypoxia Hypoxia + DTI
1.00 ± 0.08 0.65 ± 0.07*** 1.51 ± 0.19*** 0.92 ± 0.06a
Brain endothelial cell cultures were incubated in serum-free media or serum
free media plus DTI (1 nM) and exposed to hypoxia (1% O2) or normoxic
(21% O2) conditions for 6 h. The cells were incubated for 30min with 5µM of
Dihydroethidium (DHE, red) fluorescent dye and NucBlue stain (blue). ROS gen-
eration was assessed by quantitation of signal intensities of DHE stained cells
to non-stained cells. Data represent mean signal intensity of DHE stained cells
to non-stained cells ± SD from at least 3 separate experiments performed in
duplicate. ***p < 0.001 vs. Control; ap < 0.001 vs. Hypoxia.
to develop early in the pathogenesis of AD (Feng and Wang,
2012). ROS generation by nearby vascular or glia cells likely
exacerbates the injurious effects of neurotoxins such as amyloid
beta which can directly evoke oxidative stress in neurons.
The cerebral microvasculature is source of ROS including
NO in neurodegenerative diseases such as AD (Dorheim et al.,
1994; de la Torre and Stefano, 2000). Numerous studies have
suggested a link between oxidative stress and vascular inflamma-
tion (Madamanchi et al., 2005). We have previously documented
that expression of inflammatory mediators by brain endothelial
cells is increased in response to oxidative stress. In that study
oxidative stress results in increased vascular expression of IL-6
and IL-8 in apolipoprotein E-deficient mice, demonstrating fur-
ther the mechanistic links between oxidative stress and vascular
inflammation (Evola et al., 2010).
A large body of data suggests that communication between
oxidative and inflammatory processes drive a deleterious “feed-
forward” cycle that results in injury and cell death in the brain
(Yao et al., 2004; Candore et al., 2010). A key mediator of this
process could be thrombin. Oxidative stress has been shown to
increase thrombin expression in neurons and endothelial cells
(Sanchez et al., 2013). Here, we document that the oxidative
stress response to hypoxia is regulated by thrombin and that
cerebrovascular ROS generation in AD mice is also regulated
by thrombin. Thus, thrombin, in addition to its well character-
ized role as mediator of inflammation, is likely a key protein
in the development of oxidative stress under hypoxic conditions
and in AD.
The literature suggests a multifaceted role for thrombin in
AD pathogenesis. Thrombin in vitro can stimulate production
of the amyloid precursor protein (APP) and cleavage of APP
into fragments that are found in amyloid plaques of AD brains
(Igarashi et al., 1992; Ciallela et al., 1999). Thrombin is also
important for the proteolytic processing of the microtubule-
associate protein tau, a primary component of the neurofibrillary
tangle (Arai et al., 2005). Immunoreactivity for the major brain
thrombin inhibitor, protease nexin-1 is found to be significantly
decreased in AD brains, particularly around blood vessels, high-
lighting the importance of vascular-derived thrombin (Vaughan
et al., 1994). Intracerebral administration of thrombin to rodents
increases apolipoprotein E levels and results in neuronal injury
and cognitive deficits (Mhatre et al., 2004, 2006).
These data, taken together with the results of the current study
showing a key role for thrombin as mediator of hypoxia-induced
inflammation and oxidative stress, argue that thrombin inhibition
could be a useful strategy for mitigating pathology in AD. In this
regard, a study where AD patients receiving donepezil are com-
pared to those receiving donepezil plus the thrombin inhibitor
hirudin shows that patients who received hirudin demonstrate
improvements in activities of daily living, behavioral and psy-
chological symptoms of dementia as well as cognition compared
to patients on donepezil alone (Li et al., 2012). There are many
caveats regarding the therapeutic use of thrombin inhibitors
for neurodegeneration, such as the potential to cause bleed-
ing. However, the results of the current study showing a key
role for thrombin as a central mediator of hypoxic effects on
inflammation and oxidative in the cerebrovasculature, argue that
exploration to further define the mode of action of thrombin
and thrombin inhibitors in diseases such as AD where hypoxia
is an important contributing factor to disease pathogenesis is
warranted.
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